Vertex's Kalydeco combo falls short in trial; NICE nixes Celgene's Imnovid; J&J marketing new Velcade use in U.K.;

> Vertex Pharmaceuticals ($VRTX) disappointed investors with data from a cystic fibrosis combo trial in which its experimental drug VX-661 plus Kalydeco didn't improve pulmonary function as much as expected. Report

> The National Institute for Health and Care Excellence stiff-armed Celgene's ($CELG) multiple myeloma treatment Imnovid (pomalidomide), saying the third-line treatment was too costly for routine use. Report

> Johnson & Johnson ($JNJ) is rolling out a marketing campaign for Velcade in the U.K., where the drug recently won approval for a new indication in mantle cell lymphoma. Report

> Everyday Health bought the rare-disease advertising agency Cambridge BioMarketing in a deal worth about $38 million, aiming to capitalize on marketing opportunities in diseases with small patient populations. Report

> England's National Health Service is launching a directory of mental health apps it endorses for patients. Report

And Finally... An upscale lifestyle magazine just for doctors? Yep. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.